Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 46.5865. At the end of 2022 the company had a P/E ratio of 31.2.
Year | P/E ratio | Change |
---|---|---|
2022 | 31.2 | 10.85% |
2021 | 28.1 | 39.33% |
2020 | 20.2 | 5.1% |
2019 | 19.2 | 27.78% |
2018 | 15.0 | -18.22% |
2017 | 18.4 | 14.18% |
2016 | 16.1 | -31.15% |
2015 | 23.4 | 20.48% |
2014 | 19.4 | 10.09% |
2013 | 17.6 | 59.01% |
2012 | 11.1 | -32.22% |
2011 | 16.4 | -18.47% |
2010 | 20.1 | 30.58% |
2009 | 15.4 | 36.79% |
2008 | 11.2 | -50.9% |
2007 | 22.9 | 20.28% |
2006 | 19.0 | 18.28% |
2005 | 16.1 | -0.43% |
2004 | 16.1 | 16.66% |
2003 | 13.8 | 3.55% |
2002 | 13.4 | -22.51% |
2001 | 17.2 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 15.5 | -66.62% | ๐บ๐ธ USA |
Eli Lilly LLY | 142 | 204.87% | ๐บ๐ธ USA |
Sanofi SNY | 15.4 | -67.05% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 11.1 | -76.15% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.